HIV Infections Clinical Trial
— MEPSOfficial title:
Prevention Support for People Leaving Jail Study
Verified date | April 2024 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will provide HIV prevention and related support services to men who have sex with men and transgender women who have substance use disorders and are either leaving jail or recently released from jail. The researchers will compare the utilization of HIV prevention and other support services between individuals who receive routine case management provided following enrollment to those who have access to GeoPassport, a global position service (GPS)-based mobile app, incentives, and peer mentor support.
Status | Completed |
Enrollment | 215 |
Est. completion date | March 31, 2024 |
Est. primary completion date | January 11, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: 1. housed in K6G unit or within 12 months post-release from incarceration 2. ages 18-49 years 3. screens positive for Substance Use Disorder (SUD), or has sought or received SUD treatment at any time starting 12 months before the most recent incarceration until the present day. 4. reports sexual intercourse with a male or a male-to-female transgender woman in the six months prior to jail entry 5. if recruited in jail, is likely to be remain either in custody for at least four more days, but less than three more months based on scheduled court dates, current sentence, treatment plan, etc. 6. has not received an HIV diagnosis (based on self-report) 7. plans to reside in Los Angeles County for the 12 months following enrollment Exclusion Criteria: 1. does not have a smartphone and is not willing to obtain one post-release, 2. is not able to speak and understand English, and 3. does not have sufficient reading skills to operate a mobile app |
Country | Name | City | State |
---|---|---|---|
United States | God's Property | Los Angeles | California |
United States | Los Angeles County Men's Central Jail | Los Angeles | California |
United States | Los Angeles Center for Alcohol and Drug Abuse | Santa Fe Springs | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | California HIV/AIDS Research Program, Charles Drew University of Medicine and Science, Friends Research Institute, Inc., Los Angeles Centers For Alcohol and Drug Abuse |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants establishing a primary care provider who can prescribe PrEP (pre-exposure prophylaxis) | Defined as the participant identifying and completing an appointment with a primary care provider who is willing and able to prescribe HIV pre-exposure prophylaxis. Provide documentation of the appointment. | 9 months | |
Primary | Number of participants obtaining screening for PrEP | Defined as the participant completing the screening process for PrEP with an eligible provider or PrEP navigator. Provide documentation of the appointment. | 9 months | |
Primary | Number of participants who initiate PrEP regimen | Defined as the participant obtaining a prescription for PrEP, providing documentation, reporting taking the medication | 9 months | |
Primary | Number of participants who demonstrate minimal adherence to PrEP | Defined as the participant self-reporting taking prescribed PrEP at least 4 days per week over the prior 30 days | 30 days | |
Primary | Number of participants who remain on PrEP for at least 3 months. | The participant will provide documentation of filled PrEP prescriptions for 3 or more months | 3 months | |
Primary | Number of participants who undergo a HIV test every 3 months | Defined as the participant self-reporting having obtained HIV testing every 3 months over the 9 month follow-up period | 9 months | |
Primary | Number of participants who undergo a test for gonorrhea, syphilis, and chlamydia every 6 months | Defined by the participant self-reporting having obtained testing for these 3 bacterial sexually transmitted diseases (STDs) approximately every 6 months over the 9 month follow-up period | 9 months | |
Primary | Number of participants who undergo a test for hepatitis C | Defined by the participant self-reporting having obtained at least one test for Hepatitis C | 9 months | |
Primary | Number of participants obtaining treatment for substance use disorders (SUDs) in the community | Defined by the participant self-report of completing initial recommended SUD appointments within 3 months of jail release, consistent with each participant's recommended American Society of Addiction Medicine (ASAM) level of care | 3 months | |
Primary | Number of participants who remain engaged in treatment for substance use disorders (SUDs) in the community, | Defined by the participant self-reporting remaining engaged in treatment (i.e., continuing to attend meetings, counseling or other treatment activities) as defined by the recommended ASAM level of care in the 3 months prior to each follow-up interview. | 3 months | |
Secondary | Number of participants in each arm receiving care and treatment for newly diagnosed HIV or STD infections. | Self-report of whether or not participants received follow-up care and treatment for HIV, STD, and hepatitis C infections diagnosed during study follow-up (n=200) | 9 months | |
Secondary | Number of participants in each arm experiencing recidivism | Measure the comparative effectiveness of each intervention arm on reducing recidivism (n=200), quantified as the number of respondents who are reincarcerated and the total number of reincarcerations per arm over the study period. | 9 months | |
Secondary | Temporal service utilization patterns of intervention arm participants | Describe the temporal distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=100). | 9 months | |
Secondary | Geographic service utilization patterns of intervention arm participants | Report the geographic distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=100). | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |